Axiom Bio

Private

San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.axi.om/

Last Round

M&A

Nov 11, 2015

Total Funding Raised

$23.2M

Company Overview

Axiom Bio is a biotechnology company that provides AI-driven predictive models to assess molecular toxicity in drug discovery and development.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

toxicity predictiondrug discoveryin silicopredictive modelingclinical risk assessmentAI drug discoveryADMEdrug safetybiological modelingAI reasoning agentanimal testing alternativesData as a ServiceDaaSbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Axiom Bio Comps

Public and private peers based on sector, stage, and business model.

Axiom Bio comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Axiom Bio Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
M&A	Nov 11, 2015
Grant	Oct 8, 2013
Series A	Oct 8, 2013
Seed	Dec 24, 2012
Debt	Nov 7, 2012

View all Funding Rounds

Key People

Founding team and executive leadership

Brandon White

Co-Founder, CEO

Founding Team

Axiom Bio Investors

Notable investors and investment history

Axiom Bio investors
Investor	Rounds
Connecticut Innovations	Seed, Series A
NIH RADx	Grant
Zetta Venture Partners	Seed
Elm Street Ventures	Seed, Series A
Amplify Partners	Seed
Dimension	Seed
Vital Venture Capital	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 5, 2026
Grew 18% QoQ, from 22 to 26 employees.

View all signals

Axiom Bio Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Axiom Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Axiom Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California

Employee Range24

Year FoundedN/A

Last FundingNov 11, 2015

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.